Spain

In August 2026, the Spanish Network of HTA Agencies published the annual List of New and Emerging Technologies for 2025. The evaluations of a total of 66 technologies, covering multiple areas such as cardiovascular, diagnostic imaging, e-Health, endoscopy, gastrointestinal, in-vitro diagnostics, interventional radiology, men’s health, urology, neurology and neurosurgery, neuromodulation, neurovascular, obstetrics and gynecology, ophthalmology, orthopedics, pulmonary, radiotherapy, spine, and surgical procedures, have been assigned for evaluation to the relevant HTA bodies.

On July 29, 2026, the Spanish Ministry of Health launched a public consultation on proposed updates to the regulations governing the Health Cohesion Fund (FCS). The aim is to ensure that the Fund’s compensation system reflects the current healthcare needs of the National Health System. The consultation is intended to gather views before the Order updating the regulations is drafted. Comments may be submitted until September 8, 2026.

As of July 2026, the Aragon Institute of Health Sciences (IACS), one of Spain’s regional health technology assessment bodies, is conducting several HTAs in areas including diagnostic imaging, digital health, and in vitro diagnostics.

In June 2026, two HTA agencies working under the Spanish Network of HTA Agencies (RedETS) released several New and Emerging Health Technology Fact Sheets in cardiovascular, e-health, ENT, gastrointestinal, interventional radiology, neuromodulation, neurosurgery, orthopedics, and radiotherapy fields. The purpose of the Fact Sheets is to inform the prioritization of new and emerging technologies for evaluation by RedETS.

In May 2026, Spain approved its first state framework for health technology assessment (HTA) in the National Health System. Royal Decree 415/2026 establishes the rules for HTA activities used to support decisions on the incorporation, financing, pricing, reimbursement, modification of use conditions, or disinvestment of health technologies. The framework will enter into force 20 days after publication of the Decree, followed by phased implementation.

In April 2026, two HTA agencies working under the Spanish Network of HTA Agencies (RedETS) released several New and Emerging Health Technology Fact Sheets in cardiovascular, dermatology, diagnostic imaging, e-health, in-vitro diagnostics, men’s health, obstetrics and gynecology, peripheral vascular, robotic surgery and some other fields. The purpose of the Fact Sheets is to inform the prioritization of new and emerging technologies for evaluation by RedETS.

On April 20, 2026, the Common Package of Benefits of the Spanish National Health System was amended (by Order SND/356/2026, of April 13, 2026). The key changes relate to diagnostic imaging, in-vitro diagnostics, obstetrics and gynecology, and some other fields.

On April 9, 2026, the Spanish Network of HTA Agencies (RedETS) published the 2026 working plan for health technology assessments. The plan includes a wide range of topics in cardiovascular, dermatology, diagnostic imaging, e-health, endocrine, endoscopy, gastrointestinal, ICU/OR, in-vitro diagnostics, neurology and neurosurgery, neuromodulation, ophthalmology, radiology, robotic surgery, and some other fields.

In April 2026, the Canary Islands Healthcare Evaluation Service is working on several HTAs, including evaluations in e-health, IVD, neuromodulation, obstetrics and gynecology, and some other fields.

In March 2026, the Galician Agency for Health Technology Assessment (Avalia-t) is working on several HTAs, including in cardiovascular, dermatology, e-health, gastrointestinal, interventional radiology, robotic surgery, in-vitro diagnostics, peripheral vascular, neurology and neurosurgery, neuromodulation, and some other fields.

In February 2026, the Royal Decree was issued, regulating the selective financing procedure for certain health products – specifically, some types of medical aids – covered under the pharmaceutical benefit of the National Health System for non-hospitalized patients, and establishing the margins for their distribution and dispensing. The new regulation will update the old framework in place since 1996, establishing a clear, transparent, and structured system for selective financing and price-setting, with uniform criteria for the inclusion, modification, and exclusion of health products. The regulation will enter into force on July 1, 2026.

In November 2025, the Ministry of Health approved new Agreements concerning the designation of Benchmark centers, departments, and units of the National Health System (CSURs) for the treatment of rare or complex pathologies. These updates include the decision on new procedures requiring CSUR designation (surgery for complex central airway stenosis), as well as the designation, redesignation, and revocation of CSURs across multiple fields, including in the endocrine, endoscopy, gastrointestinal, nephrology and urology, neurology and neurosurgery, neuromodulation, and neurovascular fields.